This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    News
    24/10/24

    CHMP recommends approval of Venclyxto + Gazyvaro in chronic lymphocytic leukemia.- AbbVie

    Blue test tubes arranged in a line, disappearing into the background
    News
    24/10/24

    EU approves Venclyxto + Gazyva for chronic lymphocytic leukemia.- AbbVie

    A close up image of a microscope
    Clinical trial
    01/12/09

    CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

    This open-label, randomized, 3-arm study will evaluate the efficacy and safety of (obinutuzumab) RO5072759 in combination with chlorambucil as compared...

    • Source: Clinicaltrials.gov
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/05/16

    FDA approves label update for Imbruvica (ibrutinib) in chronic lymphocytic leukemia/small lymphocytic lymphoma- Janssen

    The FDA has approved an expansion to the U.S. Prescribing Information (PI) for Imbruvica (ibrutinib), from Janssen, based on data...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    01/02/20

    CHMP recommends approval of Venclyxto + Gazyvaro in chronic lymphocytic leukemia.- AbbVie

    AbbVie announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    29/12/22

    Calquence granted extension of approval by MHLW in Japan for treatment-naïve chronic lymphocytic leukaemia (including small lymphocytic lymphoma)

    AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL])

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    05/06/19

    Phase III CLL14 study of Venclexta and Gazyva meets endpoint in chronic lymphocytic leukemia.

    Genentech/Roche announced results from the pivotal Phase III CLL14 study in previously untreated chronic lymphocytic leukemia (CLL) showing that Venclexta...

    Journals
    Journal
    30/04/19

    Venetoclax in the treatment of chronic lymphocytic leukemia

    Areas covered: This article reviews the chemical structure, mechanisms of action, pharmacokinetic, and the clinical applications of venetoclax in monotherapy and in combined treatment of CLL.

    • Source: Expert Opinion on Drug Metabolism & Toxicology
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    10/06/22

    New data demonstrates Venclyxto/Venclexta combination sustained progression-free survival in chronic lymphocytic leukemia after four years of treatment.

    AbbVie announced five-year follow-up results from the Phase III CLL14 trial, finding that over 60 percent of patients with previously untreated chronic lymphocytic leukemia (CLL) who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus obinutuzumab (Gazyva) continued to show longer progression-free survival (PFS) and higher rates of undetectable minimal residual disease (MRD) after four years off treatment.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/02/22

    Genentech announces data at EHA 2021 reinforcing efficacy of Venclexta combinations in chronic lymphocytic leukemia and acute myeloid leukemia.

    Genentech, a member of the Roche Group announced the latest data from three pivotal Phase III studies of Venclexta (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021) ,. Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta in chronic lymphocytic leukemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors.

    See more